Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy.
Millis
J M
JM
Section of Transplantation, University of Chicago, Illinois 60637, USA.
Cronin
D C
DC
Newell
K A
KA
Piper
J B
JB
Woodle
E S
ES
Bruce
D S
DS
Conjeevaram
H
H
Baker
A L
AL
Thistlethwaite
J R
JR
D003365:Costs and Cost Analysis; D006084:Graft Rejection / Q000191:economics / Q000628:therapy*; D006801:Humans; D007087:Illinois; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use; D007902:Length of Stay / Q000191:economics; D016853:Muromonab-CD3 / Q000191:economics* / Q000627:therapeutic use; D016559:Tacrolimus / Q000191:economics* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus